Hospital
University of California Irvine
University of California Irvine was paid $6.87M by Medicaid between Jan 2018 and Dec 2024, across 195 billing codes. Its largest line is 0450, Emergency room services — 9.0% of everything it billed.
33Billing provider infoUNIVERSITY OF CALIFORNIA IRVINE
PLACENTIA, CA 92870
PLACENTIA, CA 92870
33aNPI1700817756assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.87M
24GClaims542,300
24DCodes billed195
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#207 of 410
Median peer was paid$6.90M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 72,312 | $605K | |
| 2019 | 76,969 | $818K | |
| 2020 | 69,225 | $798K | |
| 2021 | 81,494 | $829K | |
| 2022 | 107,452 | $1.21M | |
| 2023 | 90,710 | $1.42M | |
| 2024incomplete | 44,138 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 9.0% | 50,678 | 42,914 | $619K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.9% | 3,458 | 2,832 | $472K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.6% | 5,920 | 5,128 | $451K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.3% | 11,967 | 9,622 | $433K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 5.1% | 9,235 | 6,206 | $348K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 6,120 | 5,499 | $320K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.3% | 9,949 | 7,552 | $230K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.3% | 5,306 | 4,516 | $226K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 4,026 | 3,207 | $178K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 13,090 | 10,867 | $166K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 10,560 | 8,170 | $165K |
| 0360 | 2.3% | 6,571 | 3,598 | $160K |
183 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 8,315 | $159K |
| 99199 | Unlisted special service, procedure or report | 2.1% | 2,255 | $146K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 3,389 | $135K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 31,786 | $129K |
| 80053 | Comprehensive metabolic panel | 1.8% | 18,802 | $122K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 3,505 | $107K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 1,236 | $101K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 12,817 | $97K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 2,706 | $88K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.2% | 14,145 | $79K |
| L8699 | Prosthetic implant, not otherwise specified | 1.0% | 46 | $72K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,157 | $65K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,398 | $62K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,896 | $55K |
| 99283 | Emergency room visit (moderate) | <1% | 4,753 | $53K |
| 84484 | <1% | 9,075 | $52K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,296 | $51K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,066 | $50K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,250 | $48K |
| 93971 | <1% | 627 | $48K | |
| J3490 | Unclassified drugs | <1% | 12,786 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,483 | $45K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,540 | $44K |
| 83880 | <1% | 2,337 | $39K | |
| 99285 | Emergency room visit (most serious) | <1% | 874 | $38K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,205 | $38K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,580 | $37K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,052 | $37K |
| 81001 | <1% | 21,911 | $35K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 216 | $35K |
| 83690 | <1% | 9,413 | $35K | |
| Z7502 | <1% | 891 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,521 | $33K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 96 | $33K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,429 | $31K |
| 0710 | <1% | 5,353 | $29K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,174 | $28K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 239 | $26K |
| 0270 | <1% | 14,315 | $24K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,182 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,853 | $20K |
| 96376 | <1% | 1,611 | $19K | |
| 85730 | <1% | 6,225 | $18K | |
| 80076 | <1% | 4,915 | $18K | |
| 0160 | <1% | 2,770 | $18K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,717 | $18K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,126 | $18K |
| 84703 | <1% | 11,739 | $17K | |
| 90715 | <1% | 664 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 466 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,578 | $17K |
| 87040 | <1% | 2,491 | $16K | |
| 99284 | Emergency room visit (serious) | <1% | 1,267 | $16K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,475 | $15K |
| 73630 | <1% | 1,119 | $15K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,718 | $15K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,292 | $14K |
| 82962 | <1% | 7,594 | $14K | |
| 82550 | <1% | 3,710 | $13K | |
| 73610 | <1% | 1,030 | $13K | |
| 85610 | <1% | 6,604 | $13K | |
| 85379 | <1% | 2,175 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 178 | $13K |
| 80305 | <1% | 1,651 | $13K | |
| 94664 | <1% | 2,041 | $13K | |
| 87186 | <1% | 2,720 | $12K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,684 | $12K |
| 73030 | <1% | 890 | $12K | |
| 93970 | <1% | 137 | $12K | |
| 72100 | <1% | 639 | $11K | |
| 83605 | <1% | 2,129 | $11K | |
| 83735 | <1% | 3,316 | $11K | |
| 87077 | <1% | 2,565 | $11K | |
| 76801 | <1% | 225 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,587 | $9K |
| 88312 | <1% | 1,028 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 790 | $9K |
| A9270 | Non-covered item or service | <1% | 1,637 | $8K |
| 70486 | <1% | 115 | $8K | |
| 87070 | <1% | 1,865 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 182 | $7K |
| 73130 | <1% | 459 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,524 | $6K |
| 73564 | <1% | 367 | $6K | |
| 0762 | <1% | 806 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 585 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 38 | $5K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,274 | $5K |
| 73110 | <1% | 364 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 493 | $4K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 530 | $4K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 472 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 117 | $4K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,773 | $4K |
| 97161 | <1% | 201 | $4K | |
| 73562 | <1% | 260 | $3K | |
| 97597 | <1% | 190 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 227 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 174 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 416 | $3K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 291 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 692 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 846 | $3K |
| 84702 | <1% | 623 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 935 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 297 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 128 | $3K |
| 74018 | <1% | 279 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 581 | $2K |
| 84100 | <1% | 984 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 84 | $2K |
| 88304 | <1% | 415 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 275 | $2K |
| 0011A | <1% | 40 | $2K | |
| 86901 | <1% | 807 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 313 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 259 | $1K |
| 0250 | <1% | 1,068 | $1K | |
| 0012A | <1% | 32 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 38 | $1K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 89 | $1K |
| 72131 | <1% | 12 | $1K | |
| 0272 | <1% | 578 | $908.19 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 165 | $871.20 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 30 | $662.08 |
| 82248 | <1% | 307 | $652.27 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 21 | $626.18 |
| 71250 | <1% | 14 | $578.81 | |
| 96367 | <1% | 20 | $560.26 | |
| 71010 | <1% | 83 | $558.85 | |
| 73080 | <1% | 38 | $528.01 | |
| 88307 | <1% | 19 | $527.95 | |
| 94760 | <1% | 82 | $502.29 | |
| 99070 | <1% | 112 | $501.13 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 65 | $498.15 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 53 | $484.28 |
| 29125 | <1% | 182 | $473.99 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $452.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 67 | $450.00 |
| 86900 | <1% | 295 | $448.43 | |
| 90714 | <1% | 30 | $448.20 | |
| 80061 | Lipid panel | <1% | 64 | $427.76 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,759 | $385.37 |
| 12001 | <1% | 31 | $355.41 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 17 | $350.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 119 | $323.47 |
| 87075 | <1% | 78 | $322.77 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 44 | $290.88 |
| 87081 | <1% | 54 | $247.19 | |
| 72040 | <1% | 15 | $199.75 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 17 | $191.18 |
| 73140 | <1% | 27 | $174.81 | |
| 0750 | <1% | 481 | $146.17 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 3,309 | $135.57 |
| 82150 | <1% | 56 | $131.04 | |
| 71020 | <1% | 23 | $124.85 | |
| 83874 | <1% | 25 | $122.34 | |
| 85027 | <1% | 66 | $111.29 | |
| 82553 | <1% | 17 | $106.68 | |
| 10060 | <1% | 13 | $104.48 | |
| 99001 | <1% | 405 | $99.66 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 33 | $99.20 |
| 87420 | <1% | 28 | $94.45 | |
| 86850 | <1% | 45 | $64.88 | |
| A9150 | Non-prescription drugs | <1% | 1,363 | $54.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $52.30 |
| 82728 | <1% | 40 | $46.83 | |
| 0300 | <1% | 1,363 | $34.58 | |
| 88300 | <1% | 19 | $31.50 | |
| 29515 | <1% | 17 | $31.20 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 18 | $2.97 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,374 | $0.50 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 24 | $0.12 |
| 0370 | 0% | 57 | $0.00 | |
| 0350 | 0% | 115 | $0.00 | |
| 0255 | 0% | 17 | $0.00 | |
| 0310 | 0% | 62 | $0.00 | |
| 0636 | 0% | 303 | $0.00 | |
| 0320 | 0% | 227 | $0.00 | |
| 0760 | 0% | 143 | $0.00 | |
| G9656 | Patient transferred directly from anesthetizing location to pacu or other non-icu location | 0% | 135 | $0.00 |
| 0402 | 0% | 59 | $0.00 | |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 117 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIWABESSY, RANDOLPH (VICE PRESIDENT AND CHIEF FINANCIAL)
Parent organizationUNIVERSITY OF CALIFORNIA IRVI
| Provider | Location | Paid |
|---|---|---|
| University of California Irvine | Orange, CA | $153.06M |
| University of California Irvine | Lakewood, CA | $21.51M |
| University of California Irvine | Fountain Valley, CA | $16.83M |
| University of California Irvine | Los Alamitos, CA | $6.02M |
| Uc Regents | Fountain Valley, CA | $39K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.